Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.515 USD | +9.71% | +38.79% | -60.29% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.29% | 75.43M | |
+4.42% | 111B | |
+11.14% | 105B | |
-12.03% | 22.34B | |
-3.96% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-9.23% | 16.96B | |
+3.10% | 13.7B | |
+36.36% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio Says Enrollment in Phase 2/3 Alzheimer's Disease Trial Exceeds Projections; Shares Rise